Chris MacDonald

Chris MacDonald

InvestorPlace Contributor

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

Nano Dimension Is a Small Cap Growth Play With Large Valuation

By Chris MacDonald, InvestorPlace Contributor

Investors in NNDM stock are appearing to lose patience with the company, as it struggles to put its cash to work amid valuation concerns.

The Case for GameStop Hitting $1,000 This Year

By Chris MacDonald, InvestorPlace Contributor

Those holding on with diamond hands could be rewarded with a $1,000 share price in GME stock in the near-term, but it won't last.

COMP Stock IPO: 9 Things to Know as Compass Starts Trading Today

By Chris MacDonald, InvestorPlace Contributor

Today, shares of COMP stock are soaring following the company's highly anticipated initial public offering as investors jump aboard.

UPC Stock: Why Universe Pharmaceuticals Is Popping Higher Today

By Chris MacDonald, InvestorPlace Contributor

Here's why UPC stock is surging today on news that a broker leading the deal exercised its over-allotment option, in a surprising move.

Asensus Surgical’s Name Has Changed, But Investors’ Valuation Concerns Haven’t

By Chris MacDonald, InvestorPlace Contributor

Investors may be well-served by having a look at this company's financials before buying TRXC stock.

Load More